

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES


Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.





Express Mail No. EL 452 482 635 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Sobek *et al.*

Group Art Unit: 1635

Serial No. 09/803,165

Examiner: Nguyen, L.

Filing Date: March 9, 2001

Attorney Docket No.: 5328

For: MUTANT B-TYPE POLYMERASES
IMPROVED PERFORMANCE IN PCR

COMMUNICATION

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED
MAR 22 2002
TECH CENTER 1600/2900

Sir:

Applicants submit herewith a certified copy of European Patent

Application No. 00105155.6.

Applicant believes that no fee is due with this paper. However, if it is determined that a fee is due, please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150 (order no. 1803-280-999).

Respectfully submitted,

Dated: March 14, 2002


Rahul Pathak 42,983
(Reg. No.)

For: Jennifer Gordon (Reg. No. 30,753)
Pennie & Edmonds LLP
1155 Avenue of the Americas
New York, New York 10036
(212) 790-9090

THIS PAGE BLANK (USPTO)



Europäisches
Patentamt

European
Patent Office

Office européen
des brevets



Bescheinigung

Certificate

Attestation

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten europäischen Patentanmeldung überein.

The attached documents are exact copies of the European patent application described on the following page, as originally filed.

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet européen spécifiée à la page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

00105155.6

RECEIVED
MAR 22 2002
TECH CENTER 1600/2900

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

I.L.C. HATTEN-HECKMAN

DEN HAAG, DEN
THE HAGUE,
LA HAYE, LE
27/11/00

THIS PAGE BLANK (USPTO)



Eur päisches
Patentamt

European
Patent Office

Office européen
des brevets

**Blatt 2 der Bescheinigung
Sheet 2 of the certificate
Page 2 de l'attestation**

Anmeldung Nr.:
Application no.: **00105155.6**
Demande n°:

Anmeldestag:
Date of filing: **11/03/00**
Date de dépôt:

Anmelder:
Applicant(s):
Demandeur(s):
Roche Diagnostics GmbH
68298 Mannheim
GERMANY

Bezeichnung der Erfindung:
Title of the invention:
Titre de l'invention:
Mutant B-type DNA polymerases exhibiting improved performance in PCR

In Anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s) revendiquée(s)

Staat: Tag: Aktenzeichen:
State: Date: File no.
Pays: Date: Numéro de dépôt:

Internationale Patentklassifikation:
International Patent classification:
Classification internationale des brevets:
C12N15/52, C12N9/00

Am Anmeldestag benannte Vertragstaaten:
Contracting states designated at date of filing: AT/BE/CH/CY/DE/DK/ES/FI/FR/GB/GR/IE/IT/LI/LU/MC/NL/PT/SE/TR
Etats contractants désignés lors du dépôt:

Bemerkungen:
Remarks:
Remarques:

THIS PAGE BLANK (USPTO)

Roche Diagnostics GmbH

EPO - Munich
5

11. März 2008 328/00/EP

Mutant B-type DNA polymerases exhibiting improved performance in PCR

FIELD OF THE INVENTION

Subject of the invention is a thermostable mutant B-type DNA-polymerase having a Y-GG/A amino acid motif between the N-terminal 3'-5'-exonuclease domain and the C-terminal polymerase domain in the wild type form whereas amino acids of this motif are substituted in the mutant form of the DNA polymerase and whereas these mutant DNA polymerases are suitable for PCR reactions. Thermostable mutants according to the present invention exhibit better performance in PCR reactions compared to the wild type DNA polymerase. A further embodiment of the present invention is the use of these thermostable mutants of the B-type DNA polymerase for polymerase chain reactions (PCR) and other nucleic acid synthesizing reactions. Another subject of the present invention is a method of producing the inventive mutants, vectors and cell lines comprising genes encoding the inventive mutants.

BACKGROUND OF THE INVENTION

DNA-dependent DNA polymerases containing proof-reading activity have to coordinate two catalytic activities: the DNA polymerase activity and the exonuclease activity. For polymerase I type DNA polymerases (*E. coli* Pol I) as well as for B-type DNA polymerases, these catalytic activities are located on structurally distinct protein domains (Truniger, V., Lázaro, J., Salas, M. and Blanco, L. (1996) *EMBO J.*, 15(13), 3430-3441; Pisani, F. M., De Felice, M. and Rossi, M. (1998) *Biochemistry*, 37(42), 15005-15012). In B-type (eukaryotic-type) DNA polymerases, the coordination of the two catalytic activities was proposed to take place intramolecularly in the conserved motif Y-GG/A located between the N-terminal 3'-5' exonuclease and the C-terminal polymerization domain (Truniger, V., Lázaro, J., Salas, M. and Blanco, L. (1996) *EMBO J.*, 15(13), 3430-3441; Pisani, F. M., De Felice, M. and Rossi, M. (1998) *Biochemistry*, 37(42), 15005-15012). For the Klenow fragment of *E.coli* DNA polymerase it was described, that the editing can

be an intermolecular or intramolecular process involving dissociation and reassociation of the DNA depending on the local context (Joyce, C. M. (1989) *JBC*, 264(18), 10858-10866). Truniger et al. (Truniger, V., Lázaro, J., Salas, M. and Blanco, L. (1996) *EMBO J.*, 15(13), 3430-3441) demonstrated for the mesophile replicative DNA polymerase of bacteriophage ϕ 29 that mutations in the Y-GG/A motif can lead to phenotypes favoring either polymerisation or exonucleolysis compared to the wild type enzyme. They could show that this effect is related to altered (ss)DNA binding parameters and that the motif is important for the communication between the polymerase and exonuclease active site in a combination of structural and functional roles.

For the DNA polymerase of the thermophilic crenarchaeon *Sulfolobus solfataricus* (*Sso*) a region of 70 amino acids (region 1) involved in enzyme-DNA interaction was determined (Pisani, F. M., Manco, G., Carratore, V. and Rossi, M. (1996) *Biochemistry*, 35, 9158-9166). It is located in the connecting part between the exonuclease domain and the polymerase domain and contains the Y-GG/A motif. By mutational analysis of the amino acids in the Y-GG/A motif, it could be shown that the amino acids in this part of the enzyme determine the processivity of the proofreading function (Pisani, F. M., De Felice, M. and Rossi, M. (1998) *Biochemistry*, 37(42), 15005-15012). Based on the crystal structure of bacteriophage RB69 DNA polymerase, Truniger et al. proposed a direct interaction of the tyrosine with the phosphodiester bond between the two nucleotides preceding the one acting as template (Truniger, V., Blanco, L. and Salas, M. (1999) *J. Mol. Biol.*, 286, 57-69).

DESCRIPTION OF THE INVENTION

The subject of the present invention was to provide thermostable DNA polymerases exhibiting an improved performance in PCR. Especially, thermostable mutants of a B-type DNA polymerase are provided which exhibit improved PCR performance. The inventive mutants of the B-type DNA polymerase have mutations in the Y-GG/A amino acid motif. Preferred mutations refer to the position of the tyrosine in the Y-GG/A amino acid motif. Other mutations affecting the motif could also influence the performance of B-type DNA polymerases in PCR.

According to the present invention an improved performance of a DNA polymerase in PCR is defined as a performance that results in higher yields of PCR product, or the amplification of

longer DNA targets. Additionally, improved PCR performance can be defined as improved fidelity during the amplification process.

Preferred mutant B-type DNA polymerases have mutations at the position of the tyrosine in the Y-GG/A amino acid motif. Preferred mutants of B-type DNA polymerases according to the present invention have phenylalanine, tryptophan or histidine at the position of the tyrosine. Other preferred mutants of B-type DNA polymerases according to the present invention have asparagine or serine at the position of the tyrosine. These mutant polymerases described here, in which the tyrosine of the Y-GG/A motif was substituted, exhibit an improved performance in PCR.

In a preferred embodiment the inventive mutant B-type DNA polymerase is a mutant of a B-type DNA polymerase obtainable from Euryarchaea, more preferably from *Thermococcus aggregans* (*Tag*). Especially preferred is a mutant of a B-type DNA polymerase from *Tag* of about 94 kDa size with a temperature optimum of $\geq 80^\circ\text{C}$ and the ability to perform polymerase chain reactions.

The present invention is described in detail for the B-type DNA polymerase from *Thermococcus aggregans*, but the invention could also be applied to other B-type DNA polymerases. Preferably to those B-type DNA polymerases showing a high degree of homology ($\geq 80\%$) to the DNA polymerase from *Thermococcus aggregans*.

The B-type DNA polymerase from *Thermococcus aggregans* exhibits a high degree of amino acid sequence homology to B-type DNA polymerases of other *Thermococcus* species. The homology of the DNA polymerases was calculated using the programm Blast 2 (Tatusova, T.A. and Madden, T.L. (1999) *FEMS Microbiol. Lett.* 174, 247 – 250). The homology of the B-type DNA polymerase from *Thermococcus aggregans* to the homologue enzymes from *Thermococcus* species is: 93% (*T. litoralis*), 87% (*T. gorgonarius*), 86% (*T. furiosus*) and 87% (*T. spec. 9N7*). The homology of the *Tag* DNA polymerase to polymerases from *Pyrococcus* species is: 86% (*P. abyssi*), 86% (*P. horikoshii*), 86% (*P. spec KOD*) and 85% (*P. furiosus*). A lower homology is calculated to other B-type DNA polymerase from different euryarchaeota: 59% (*Methanococcus jannaschii*), 56% (*Methanococcus voltae*), 51% (*Methanobacterium thermoautotrophicum*) and 56% (*Archaeoglobus fulgidus*). To B-type DNA polymerases from crenarchaeota and bacteriophages the homology is found as follows: 46% (*Sulfolobus solfataricus*), 42% (*Sulfolobus acidocaldarius*), 41% (*Sulfurisphaera ohwakuensis*), 51% (*Aeropyrum pernix*), 40% (*Pyrodictium occultum*), 43% (*Cenarchaeum symbiosum*), 38% (bacteriophage T4) and 39% (bacteriophage RB69).

As described above several mutations in the Y-GG/A motif were performed for the *Sulfobolus solfataricus* (*Sso*) and the ϕ 29 DNA polymerases. The observed effects on polymerase activity (pol) and exonuclease activity (exo) of these mutations do not completely correspond to the effects obtained for the *Tag* DNA polymerase. Thus the effect of the mutations on the performance of the mutants in PCR was not predictable.

The mutant Y387F of the *Tag* DNA polymerase exhibits a higher pol/exo ratio compared to the wild type *Tag* DNA polymerase. Similar results were described for *Sso* and ϕ 29 DNA polymerase. The mutant G389A displays the opposite effect than the corresponding mutant in ϕ 29 DNA polymerase: while G \rightarrow A in *Tag* DNA polymerase almost knocks out polymerase activity, in ϕ 29 DNA polymerase G \rightarrow A mutant this activity is clearly enhanced. For mutants of the *Sso* DNA polymerase a change of exonuclease processivity was described. Again, this was not observed for mutants of the B-type *Tag* DNA polymerases. Thus, a prediction of the effect of analogous mutants in the Y-GG/A motif could not be made.

In summary, although it has been described in the prior art that the Y-GG/A motif plays a role in the coordination of the DNA polymerase activity and the exonuclease activity, the observed changes of the pol/exo ratio of the prior art DNA polymerases do not strictly correlate to the changes observed for the inventive mutants of the *Tag* DNA polymerase. Furthermore, it has not been described that the Y-GG/A motif is important for the performance of B-type DNA polymerase in PCR. Additionally, there is no correlation between the changes of the pol/exo ratio and the improvement of the performance of DNA polymerases in PCR. For instance, the mutant Y387H does not exhibit a change of pol/exo ratio compared to the wild-type, but it exhibits improved performance in PCR. Furthermore, a significant enhancement of fidelity was observed for the mutants Y387N and Y387S of *Tag* DNA polymerase.

Results obtained for the mutants of *Tag* DNA polymerase are described in more detail below.

Enzymatic activities of wild type and mutant *Tag* DNA polymerases

The enzymatic activities of the wild type enzyme and the mutants of *Tag* DNA polymerase were determined and analyzed (Figure 1). The DNA polymerase activity was determined as described in Example 2. According to the effect of the mutations on the polymerase activity three groups of

mutants were defined: i) mutants with enhanced DNA polymerase activity (mutant Y387F), ii) mutants having a similar or slightly reduced DNA polymerase activity compared to the wild type (mutants Y387W and Y387H) and iii) mutants with reduced DNA polymerase activity (mutants Y387N, Y387S, G389A).

The exonuclease activity was determined as described in Example 3. According to the effect of the mutations on the exonuclease activity two groups of mutants were defined: i) mutants with similar exonucleolytic activity as the wild type enzyme (mutants Y387F, Y387W, Y387H), ii) mutants with enhanced exonuclease activity (mutants Y387N, Y387S, G389A) in comparison to the wild type enzyme.

From the data obtained for polymerase activity and exonuclease activity the ratios of both activities (pol/exo) were calculated for the wild type enzyme and the mutants of *Tag* DNA polymerase (Figure 1). Three mutants showed a higher or similar pol/exo ratio as the wild type enzyme (mutants Y387F, Y387W, Y387H). Three mutants showed a clearly reduced pol/exo ratio in comparison to the wild type enzyme (mutants Y387N, Y387S, G389A).

PCR performance

Wild type and mutant enzymes were submitted to polymerase chain reactions on lambda DNA in a buffer optimized for this purpose. All mutants except for mutant G389A were able to perform PCR, but yielded different amounts of product with a constant amount of enzyme (1 pmol). With increasing length of the DNA target, differences in performance of the enzyme were shown (Fig. 2). With 1 pmol of the mutants Y387S, Y387N and G389A no PCR product could be obtained for the amplification of a 3.3 kb fragment. 1 pmol of the wild type DNA polymerase could not amplify fragments of 5.0 kb length. The mutants Y387W, Y387F and Y387H were able to amplify a fragment of 7.5 kb length. As control *Taq* DNA polymerase, *Pwo* DNA polymerase and ExpandTM High Fidelity PCR System (Roche Molecular Biochemicals) were used.

The differences in PCR performance were also shown by the amplification of a 2 kb fragment applying different elongation times in the PCR runs. Under these conditions, all enzymes tested except the mutant G389A were able to amplify a 2 kb fragment at an elongation time of 90 sec/cycle. The mutants Y387F, Y387W and Y387H were able to amplify the fragment at a reduced elongation time of 40 sec/cycle. The mutant Y387H was able to amplify the target in a elongation time of 30 sec/cycle (Fig. 3).

Exonuclease processivity

The exonuclease processivity of the enzymes was studied in an experiment based on the heparin trap method (Reddy, M. K., Weitzel, S. E. and von Hippel, P. H. (1992) *J. Biol. Chem.*, 267(20), 14157-14166; Pisani, F. M., De Felice, M. and Rossi, M. (1998) *Biochemistry*, 37(42), 15005-15012). A constant amount (1 pmol) of *Tag* DNA polymerase or its mutants was incubated for 4 minutes at 68 °C with a 5'-DIG-labelled 24mer oligonucleotide in the absence of nucleotides. In the absence of heparin, the oligonucleotide was continually degraded by the *Tag* enzymes (positive control, Fig. 4, lanes “-“). The function of the heparin trap method was demonstrated by addition of heparin and MnCl₂ before the binding of the enzyme (negative control, Figure 4, lanes B). Single turnover conditions (addition of heparin and MnCl₂ to start the reaction after the binding of enzyme) resulted in exonucleolytic degradation of the oligonucleotide by the *Tag* DNA polymerases (Fig. 4, lanes A). The enzymes showed differences in the exonucleolytic activity as shown by the different amounts of remaining oligonucleotide that was not degraded. However, for all enzymes tested the oligonucleotide was degraded to a similar extent (8 nt). This indicates a similar exonuclease processivity for the enzymes.

The *Thermococcus gorgonarius* DNA polymerase, which exhibits a strong exonuclease activity, was used as a positive control. It degraded the 24mer oligonucleotide in the absence of heparin to oligonucleotides of less than 15 bases length (Figure 4, lane “-“). Under single turnover conditions a strong degradation (11 nt) of the oligonucleotide is observed (Figure 4, lane “A“).

Fidelity

The error rates in amplification were determined for the mutant enzymes and the wild type DNA polymerase. The PCR-based fidelity assay described by Frey and Suppmann (Frey, M. and Suppmann, B. (1995) *Biochemica*, 2, 34-35) was used. This method is based on the amplification, circulation and transformation of the pUC19 derivative pUCQ17, which contains a functional *lacI*^q allele (Barnes, W. M. (1994) *Proc. Natl. Acad. Sci. USA*, 91, 2216-2220). PCR-derived mutations in *lacI* result in a de-repression of the expression of *lacZα* and subsequent formation of a functional β-galactosidase enzyme, which can be detected on X-Gal indicator plates.

In five independent runs, a mean error rate of 5.0x10⁻⁶ was found for the wild type *Tag* DNA polymerase. This value is in between the mean error rates of 1.8x10⁻⁶ for ExpandTM High Fidelity PCR System (Roche Molecular Biochemicals) and 1.3x10⁻⁵ for *Taq* DNA polymerase

(Roche Molecular Biochemicals) determined in the corresponding experiments. For a better comparison of the data, we plotted the quotient of the error rate determined for *Taq* DNA polymerase divided by the error rates determined for the *Tag* DNA polymerase and its mutants. In the independent experiments the error rate for *Taq* DNA polymerase varied from 1.2 to 3.05×10^{-5} .

Figure 5 shows the quotients of the error rates of the wild type enzyme and mutants of *Tag* DNA polymerase. The error rates of the mutants showing improved PCR performance (Y387W, Y387F, Y387H) did not significantly differ from the values obtained for the wild type enzyme. The mutants with enhanced exonuclease activity (Y387N, Y387S) showed improved fidelity rates (Figure 5). For the mutants Y387N and Y387S mean error rates of 6.3×10^{-7} and 6.2×10^{-7} were determined.

In contrast to the $\phi 29$ DNA polymerase and the *Sso* DNA polymerase, the *Tag* DNA polymerase, is suited for PCR. The mutant enzymes (Y387F, Y387W, Y387H) with an aromatic amino acid in the position of the tyrosine showed a similar or only slightly enhanced DNA polymerase activity (mutants Y387F, Y387W, Y387H) but an improvement in PCR performance.

In the fidelity assay it was found that the mutants Y387F; Y387W and Y387H showed no significant change in their error rate. By contrast, the mutants Y387N or Y387S showed higher exonuclease activity and displayed an improved fidelity.

Subject of the present invention is also a method of producing the inventive B-type mutants comprising the following steps: cloning and mutagenesis of the gene, followed by the expression and purification of the protein.

Subject of the present invention is a DNA encoding for a thermostable B-type DNA polymerase having a Y-GG/A amino acid motif between the N-terminal 3'-5' exonuclease domain and the C-terminal polymerase domain in the wild type enzyme whereas the tyrosine of this motif is substituted in the mutant enzyme of the polymerase and whereas this mutant DNA polymerase is suitable for PCR.

Preferably, said DNA in wild type form is obtainable from Euryarchaea, more preferably from *Thermococcus aggregans* (*Tag*). Subject of the present invention is also a vector containing the inventive DNA. Suitable vectors are e.g. the following: pET14b/15b/16b/19b (Novagen); pRSET

(Invitrogen); pTrcHis (Invitrogen); pHAT10/11/12 (Clontech); pPRO Tet.E/Lar.A (Clontech); pCALn/n-EK (Stratagene); pGEMEX-1/-2 (Promega).

Furthermore, subjects of the present invention are also cells comprising the above vector. Suitable cells are e.g. *E.coli* BL21, BL21(DE3), BL21(DE3)pLysS, BL21(DE3)pLysE, DH5 α PRO, JM109 (DE3), TOP10 in combination with the vectors recommended by the suppliers. The gene may have to be subcloned and the protein purification procedure may have to be adapted in the case of different expression vectors.

A sample of the recombinant strain expressing *Tag* DNA polymerase was deposited with the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) Mascheroder Weg 1b, D-38124 Braunschweig (DSM No. 13224).

A further subject of the invention is the use of the inventive mutant enzymes for synthesizing nucleic acids e.g. in PCR reactions.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

EPO - Munich
5

11. März 2000

Figures:**Figure 1.**

Table showing the relative polymerase activities (Pol) and 3'-5'-exonuclease activities (Exo) of *Tag* DNA polymerase and its mutants on double-stranded DNA.

Assays were carried out as described in example 2 and 3, respectively. The activities are expressed as percentage of the activity obtained for the wild-type *Tag* DNA polymerase.

Figure 2.

PCR with *Tag* DNA polymerase mutants.

Tag DNA polymerase mutants (1 pmol) were incubated in a 50 µl total volume with 10 ng of lambda DNA as template and 30 pmoles of a primer set designed to yield the indicated fragment lengths, 200 µM dNTPs and the suitable PCR buffer. Reactions were performed with 10 cycles of 10 sec 94 °C, 30 sec 57 °C and 3.0 min (A), 4.3 min (B) or 7.0 (C) min of elongation time at 72 °C followed by 20 cycles with elongation times increasing by 20 sec/cycle. After the PCR 5 µl sample were submitted to electrophoresis on a 1% agarose gel. For the control reaction 2.5 U of *Taq* DNA polymerase, *Pwo* DNA polymerase or ExpandTM High Fidelity PCR System were used. The labeling of the lanes is described in the legend of figure 6.

Figure 3.

Time-dependent polymerase chain reaction.

1% agarose gels showing 2 kb PCR products from reactions performed with different elongation time (90 sec, 40 sec, 30 sec as indicated) to determine the minimal elongation time.

1 pmol of each *Tag* DNA polymerase mutant or wild type enzyme was added to a mix of 10 ng lambda DNA and primers designed to yield 2 kb DNA fragments. Labeling of the lanes is described in the legend of figure 6. For each mutant duplicate reactions were performed. Right lane of each gel *Pwo*: 2.5 U *Pyrococcus woesei* DNA polymerase (Roche Molecular Biochemicals) as control reaction. Left lane of each gel: Molecular weight marker VI (Roche Molecular Biochemicals). In the 40 sec reaction, mutant GA was omitted. In the 30 sec reaction, for the mutant YS only one reaction was run on the gel.

Figure 4.**3'-5'-exonuclease processivity.**

The *Tag* DNA polymerase mutants tested are indicated on top of the figure. *Tgo* DNA polymerase was used as a control reaction (incubation for 30 sec). Reactions for wild type and mutants of *Tag* DNA polymerase were performed for 4 minutes at 68 °C after preincubation for 1 minute at 68°C. Lane "P" is the control reaction (24 mer 5'-DIG-labelled primer without incubation), lane "-": reaction without heparin (positive control); lane "B": reaction with heparin and MnCl₂ added before addition of the enzyme (negative control); lane "A": heparin and MnCl₂ added after the enzyme (reaction under single turnover conditions).

Figure 5.**Fidelity of *Tag* DNA polymerase mutants.**

The fidelity of *Tag* DNA polymerase and its mutants was expressed in relation to the fidelity of *Taq* DNA polymerase. A quotient of 1 means that the polymerase has the same error rate as *Taq* DNA polymerase (mean value 1.3x10⁻⁵). Values >1 reflect the factor by which a polymerase shows less errors than *Taq* DNA polymerase. The bars correspond to mean values calculated from 2-5 independent experiments, error bars missing are smaller than 0.36. Abbreviations for enzymes are as indicated in legend to figure 6. As controls *Pyrococcus woesei* DNA polymerase (Roche Molecular Biochemicals) and Expand High Fidelity PCR System (Roche Molecular Biochemicals) were used („Taq/Pwo“ and „Taq/HiFi“).

Figure 6.**SDS-PAGE gel analysis of purified mutant proteins.**

1 µg of each mutant was submitted to electrophoresis on an 10% SDS-PAGE gel. Left: MW, molecular weight marker; WT, *Thermococcus aggregans* wild type DNA polymerase; YF, YW, YS, YN, YH are the corresponding mutants with an exchange at the position of tyrosine 387 to phenylalanine, tryptophan, serine, asparagine, histidine, respectively. GA, mutation of glycine 389 to alanine in the gene of the *Thermococcus aggregans* DNA polymerase. All mutants showed the same chromatographic behaviour and solubility as the wild type enzyme.

Figure 7.**Qualitative exonuclease assay.**

A DNA molecular weight marker was used as substrate to test the exonucleolytic activity (DNA molecular weight marker II (MW II), Roche Molecular Biochemicals). 1 µg of MW II was incubated for 6 h at 65 °C with 1 pmol of each variant of *Tag* DNA polymerase in the presence (A) or absence (B) of 200 µM dNTP. *Tag* mutants are named as explained in legend of figure 6. Exonucleolytic degradation take place only in the absence of deoxynucleotides. The qualitative ranking of the proteins in terms of exonuclease activity is GA > YN > YS > YH > YF = YW = WT.

Figure 8.

Consensus sequence motif for B-type DNA polymerases from the order of *Thermococcales* derived from a multiple alignment of amino acid sequences of euryarchaeal and crenarchaeal B-type DNA polymerases.

A region of 24 amino acids containing the Y-GG/A motif was analyzed with the ClustalW Software program (Higgins, EMBL Heidelberg, Germany). In addition to the amino acids conserved in all archaeal B-type DNA polymerases (like the Y-GG/A motif), a consensus sequence "E--RR-R-----G(Y)-KE-EE--LWE-" can be defined. This sequence is found in the sequence of all DNA polymerases belonging to the order of the *Thermococcales* and coincides with a homology of >80% of the DNA polymerases.

The sequences of the crenarchaeal species *Sulfolobus solfataricus*, *Sulfolobus acidocaldarius*, *Pyrobaculum islandicum*, *Pyrodictium occultum*, *Aeropyrum pernix*, *Sulfurisphaera ohwakuensis* and the sequences of several euryarchaeal species *Thermococcus* ("T."), *Pyrococcus* ("P.") and *Methanococcus* ("M.") were aligned.

Figure 9.

DNA sequence and deduced amino acid sequence of recombinant wild type *Tag* DNA polymerase.

Three inteins found in the native gene (Acc. No. Y13030) were deleted by PCR (Niehaus, F., Frey, B., Antranikian, A. (1997) *Gene*, 204, 153-158). Four mutations leading to amino acid exchanges were introduced during PCR. The amino acid exchanges (native→recombinant) are: L3F, A404T, S410C and L492H.



Example 1**Site-directed mutagenesis and expression of *Tag* DNA polymerase mutants**

The cloning of the gene of *Tag* DNA Polymerase (polTY) was described earlier (Niehaus, F., Frey, B., Antranikian, A. (1997) *Gene*, 204, 153-158). Overexpression of *Tag* DNA Polymerase in *E. coli* was achieved by subcloning its encoding gene into the IPTG-inducible pET15b vector (Novagen) containing an N-terminal His-Tag for purification (the resulting plasmid was named pET15b-*TagPol*).

The mutants presented in this study were prepared in polymerase chain reactions using primers containing the desired mutations as a mismatch. The forward primer was universally "Kpn-fw", matching to a sequence about 100 bp upstream of the mutation site and contained a *KpnI* restriction site of the polTy gene. The reverse primers contained a *SnaBI* restriction site and additionally the desired mutation. The sequences of the oligonucleotides were as follows (mismatch sites for mutagenesis underlined):

Kpn-Fw	5'-GCAACCTTGTAGAGTAGAGTGGTACCTGTTAAGGG-3';
TagY387F	5'-GCCTCTTCGGCTTTACGTATCCTCCCAGGA <u>AAGT</u> AGTCC-3',
TagY387H	5'-GCCTCTTCGGCTTTACGTATCCTCCCAGGT <u>GAGT</u> AGTCC-3',
TagY387N	5'-GCCTCTTCGGCTTTACGTATCCTCCCAGGT <u>TAGT</u> AGTCC-3',
TagY387S	5'-GCCTCTTCGGCTTTACGTATCCTCCCAGGG <u>AAGT</u> AGTCC-3',
TagY387W	5'-GCCTCTTCGGCTTTACGTATCCTCCCAG <u>CCAAGT</u> AGTCC-3',
TagG389A	5'-GCCTCTTCGGCTTTACGTATCC <u>AGCCAGGT</u> AAGTCC-3'.

PCR reactions were carried out with Expand™ High Fidelity PCR System (Roche Molecular Biochemicals) using the following program: 2 min 94 °C, 30 cycles of 10 sec 94 °C, 30 sec 55 °C, 30 sec at 72 °C. The resulting 139 bp fragments were digested with the restriction enzymes *KpnI* and *SnaBI* yielding a 101 bp fragment that was ligated into pET15b-*TagPol* linearized with the restriction enzymes *KpnI* and *SnaBI*. The cloned DNA fragments were sequenced to confirm the presence of the desired mutations.

For protein expression, *E. coli* BL21 (DE3) cells were transformed with the expression vector pET15b-*TagPol*. Three to five colonies were inoculated in 15 ml of LB medium supplemented with 100 µg Ampicillin per ml and grown to OD_{600nm} 0.3. An aliquot (10 ml) of the preculture was used to inoculate 500 ml of LB medium and incubated while shaking at 37°C. At OD_{600nm}= 0.6 expression was induced by addition of IPTG (final concentration: 1 mM). After incubation

for 3 hours cells were harvested by centrifugation and suspended in 50 mM Tris-HCl/pH 7.5, 10 mM KCl, 0.5 mM EDTA, 4 mM MgCl₂, 5 mM DTT. Cells were sonicated on ice and the crude extract was heated for 15 min to 80 °C. Cell debris was removed by centrifugation (30 min, 30 000 x g at 4 °C).

The supernatant was applied to a Blue Sepharose 3G-A column (Pharmacia) equilibrated with buffer A (50 mM Tris-HCl/ pH 7.5, 10 mM KCl, 4 mM Mg Cl₂). The protein was eluted with a gradient of 0.01-1.5 M KCl. Active fractions were pooled and dialyzed against 20 mM Tris-HCl /pH 7.9, 5 mM imidazole, 500 mM NaCl. The sample was applied to a Ni-chelate column (Novagene) equilibrated in the same buffer and eluted with a gradient of 0.005 - 1 M imidazole. Active fractions were pooled and dialyzed against storage buffer (50 mM Tris-HCl/pH 7.5, 100 mM KCl, 0.5 mM EDTA, 5 mM DTT, 50% glycerol). The enzymes were pure as shown by SDS gel electrophoresis (Figure 6).

Example 2

DNA polymerase assay

The DNA polymerase activity was determined by measuring the incorporation of α -(³²P)dCTP in a DNA substrate. The test mix (50 µl) contained 5 µl 10x Tag reaction buffer (100 mM Tris-HCl /pH 8.9, 750 mM KCl, 15 MgCl₂, 100 mM CHAPS), 200 µM of each dATP, dGTP, dTTP, 100 µM dCTP, 1 mCi α -(³²P)dCTP, 1 µg of M13mp9 ssDNA annealed with 0.3 µg M13 primer. Assays were performed with 2 and 3 µl of enzyme in three different dilutions (final amount of enzyme 2.5 to 15 fmoles) yielding six reactions to calculate a mean value. As a reference *Pwo* DNA polymerase was used. The DNA/primer mix was prepared by heating 277.2 µg M13mp9 ssDNA (Roche Molecular Biochemicals) and 156 µg M13 sequencing primer (17mer forward primer, Roche Molecular Biochemicals) for 30 minutes to 55 °C and then cooling it for 30 minutes to room temperature.

Assay reactions were incubated for 30 minutes at 65 °C, stopped on ice by addition of 500 µl of 10% TCA (4 °C) and kept on ice for another 10 minutes. Samples were filtered over GFC-filter (Whatman), filters washed three times with 5% TCA, dried and submitted to β -counting in 2 ml of scintillation fluid. One unit is defined as the amount of enzyme necessary to incorporate 10 nM dNTP into acid insoluble material at 65 °C in 30 minutes.

Example 3

Exonuclease Assays

Activity Assay

3 µl (300 ng) of enzyme (approximately 5 Units of polymerase activity) were incubated with 5 µg of 3H-labelled calf thymus DNA for 4 hours at 65 °C in a buffer containing 10 mM Tris-HCl/pH 8.9, 75 mM KCl, 1.5 MgCl₂, 10 mM CHAPS. Radioactivity liberated from calf thymus DNA was measured in a scintillation counter.

The assay used does not discriminate between the 3'-5' exonuclease activity and the 5'-3' exonuclease activity. 5'-3'-exonuclease activity has not been detected pheno- or genotypically in B-type polymerases of *Thermococcales* (Perler, F. B., Kumar, S. and Kong, H. (1996) *Adv. Prot. Chem.*, 48, 377-435). Thus the values obtained can be regarded as 3'-5'-exonuclease activity.

In another assay, 1 µg of molecular weight marker II (Roche Molecular Biochemicals) were incubated in same buffer as above with 5 U of the indicated protein with or without 200 µM dNTP in a final volume of 50 µl for 6 hours at 65 °C. The reaction products were separated by electrophoresis on 1% agarose gels.

3'-5' Exonuclease processivity assay

The previously described heparin trap method was used (Reddy, M. K., Weitzel, S. E. and von Hippel, P. H. (1992) *J. Biol. Chem.*, 267(20), 14157-14166; Pisani, F. M., De Felice, M. and Rossi, M. (1998) *Biochemistry*, 37(42), 15005-15012). A reaction mix (10 µl) containing 10 mM Tris-HCl/pH 8.9, 75 mM KCl, 10 mM CHAPS and 0.5 pmoles of a 5'-DIG-labeled 24mer oligonucleotide was prewarmed for 1 minute at 68 °C in a thermocycler. Unless otherwise noted, 1 pmol of the enzyme was preincubated for 1 minute at 68 °C with the substrate. The reaction was started by addition of MnCl₂ (final concentration: 4 mM) and heparin (final concentration: 1 mg/ml) to ensure single turnover conditions. After incubation for 4 minutes, the reaction was stopped by the addition of 5 µl of formamide buffer (80% formamide, 10 mM EDTA, 1 mg/ml bromophenol blue, 1 mg/ml xylene xyanol). The efficiency of the heparin trap was checked in a control reaction by adding heparin and MnCl₂ prior to the addition of the enzyme. The samples were denatured for 3 minutes at 90 °C and subjected to denaturing gel electrophoresis on a 17.5 % polyacrylamide/8 M urea gel. Gels were blotted to a positively charged nylon membrane (Roche Molecular Biochemicals) and the blots developed with CPD-Star (Roche Molecular Biochemicals) according to the manufacturers instructions.

Example 4***lacI*-based PCR fidelity assay**

We used the *lacI*-based PCR fidelity assay described by Frey and Suppmann (Frey, M. and Suppmann, B. (1995) *Biochemica*, 2, 34-35). This method is based on the amplification, circularization and transformation of the pUC19 derivative pUCQ17, which contains a functional *lacI^q* allele (Barnes, W. M. (1994) *Proc. Natl. Acad. Sci. USA*, 91, 2216-2220). PCR-derived mutations in *lacI* result in a de-repression of the expression of *lacZα* and subsequent formation of a functional β-galactosidase enzyme, which can be easily detected on X-Gal indicator plates.

The truncated *lacI* gene of pUC19 was substituted by a functional copy of *lacI^q*. A 178 bp *Pvu II*-*Afl III* fragment was replaced by a 1121 bp DNA fragment encoding *lacI^q*. The α-complementing *E. coli* strain DH5α, once transformed with the resulting plasmid pUCIQ17 (3632 bp), produces white (*LACI⁺*) colonies on LB plates containing ampicillin (100 µg/ml) and X-Gal (0,004% w/v). For the PCR, pUCIQ17 was linearized by digestion with *Dra* II and used as a template in an amount of 1 or 10 ng. Both primers have *Cla* I cleavage sites at their 5' ends. Oligonucleotide Cla33 (34mer, 24 matches: 5'-AGC TTA TCG ATG GCA CTT TTC GGG GAA ATG TGC G-3') and Oligonucleotide Cla55 (36mer, 26 matches: 5'- AGC TTA TCG ATA AGC GGA TGC CGG GAG CAG ACA AGC-3') resulted in a PCR product of 3493 bp.

The reactions were performed with 1 or 5 pmol of protein in the *Tag* polymerase PCR buffer described below or for the control reactions in the manufacturers PCR buffers with 2.5 U of enzyme. The cycle conditions were 10 sec denaturation at 94 °C, 30 sec annealing at 57 °C and 4 min elongation at 72 °C for 18, 24 or 30 cycles depending on the enzyme.

After PCR, the yield of amplification product was determined at (OD_{260nm} or in agarose gel) and the DNA fragments submitted to phenol/chloroform extraction to eliminate any protein. After digestion with *Cla*I, the DNA fragments were purified from a preparative agarose gel. Ligation reactions were carried out with the Rapid Ligation Kit (Roche Molecular Biochemicals), the reactions contained 30 ng DNA. The resulting circular plasmids were transformed in *E. coli* DH5α as described by Hanahan (Hanahan, D. (1983) *J. Mol. Biol.*, 166, 557-580) and plated on LB Amp/X-Gal plates described above. After incubation overnight at 37 °C, blue and white colonies were counted. The error rate (f) per bp was calculated with a rearranged equation published by Keohavong and Thilly (Keohavong, P. and Thilly, W. G. (1989) *Proc. Natl. Acad. Sci. USA*, 86, 9253-9257): f = -lnF / d x b bp.

Where F is the fraction of white colonies (white colonies/ total colonies); d is the number of DNA duplications: $2^d = \text{output DNA}/\text{input DNA}$ and b is the effective target size (1080 bp) of the *lacI* gene. There are 349 phenotypically identified (by colour screening) single-base substitutions (non-sense and mis-sense) at 179 codons (approximately 50% of the coding region) within the *lacI* gene. (Provost, G. S., Kretz, P. L., Hamner, R. T., Matthews, C. D., Rogers, B. J., Lundberg, K. S., Dycaico, M. J. and Short, J. M. (1993) *Mut. research*, 288, 133-149). Frameshift errors which may occur at every position in the 1080 bp open reading frame of *lacI*, are not taken into account because little information is available for the specific polymerases used in PCR systems except for *Taq* DNA polymerase.

Example 5

Polymerase Chain Reactions

PCR was performed in a buffer optimized for *Taq* DNA polymerase and its mutants: 10 mM Tris-HCl/pH 8.9, 75 mM KCl, 1.5 MgCl₂, 10 mM CHAPS, 200 µM dNTP. 10 ng of λ DNA were used as a template and 30 pmol of each primer (20 bp, designed to yield the products of the desired length):

Lambda 1, universal forward primer: 5'-GAT GAG TTC GTG TCC GTA CAA CA-3',

Lambda 3.3: 5'-CTC ATC AGC AGA TCA TCT TCA GG-3',

Lambda 8: 5'-ACT CCA GCG TCT CAT CTT TAT GC-3',

Lambda 9: 5'-GAT GGT GAT CCT CTC TCG TTT GC-3'.

Lambda 3.3, 8 and 9 were used as reverse primers for the amplification of 3 kb, 3.5 kb and 7.5 kb fragments respectively.

Template, primers and nucleotides were prepared in mix 1 in a volume of 25 µl. Then 25 µl of mix 2 containing the buffer and enzyme (1 pmol *Taq* wild type or mutant; or 2.5 U control enzyme) were added. All reactions were prepared in duplicate. The amplification was performed in a 2400 GeneAmp thermocycler (Perkin Elmer). The cycle conditions were: 2 min at 94 °C, 10 cycles with 10 sec denaturation at 94 °C, 30 sec annealing at 58 °C and elongation at 72 °C. Elongation times depended on the length of the product (3 min for 3.3 kb, 4.3 min for 5 kb and 7 min for 7.5 kb). Another 20 cycles were performed with increasing the elongation times by 20 sec/cycle. The reaction was finished by 7 minutes at 72 °C. The tubes were kept at 4 °C until separation by electrophoresis on 1% agarose gels.

The improvement of the PCR performance of the mutants was also studied in a "time-dependent PCR". A 2 kb fragment was amplified from lambda DNA as described above. In these studies the

elongation time of the PCR was stepwise reduced (90 sec, 40 sec, 30 sec) to determine for each enzyme the minimal elongation time that was sufficient to amplify the 2 kb fragment. The following primers were used:

Lambda 1, universal forward primer: 5'-GAT GAG TTC GTG TCC GTA CAA CA-3',

Lambda 6, reverse primer: 5'-CTT CAT CAT CGA GAT AGC TGT CG-3'.

The temperature profile was as described above. The elongation times were kept constant over 30 cycles.

THIS PAGE BLANK (USPTO)

Claims

1. A thermostable mutant B-type DNA polymerase having a Y-GG/A amino acid motif between the N-terminal 3'-5'-exonuclease domain and the C-terminal polymerase domain in the wild-type form of the polymerase whereas preferably the tyrosine of this motif is substituted in the mutant form of the polymerase and whereas this mutant DNA polymerase is suitable for polymerase chain reactions.
2. A mutant B-type DNA polymerase according to claim 1 having an amino acid with an aromatic side chain at the position of the tyrosine.
3. A mutant thermostable B-type DNA polymerase according to claim 1 having a Y→F,Y→W or Y→H mutation.
4. A mutant B-type DNA polymerase according to claim 1 having an amino acid with an hydrophilic side chain at the position of the tyrosine.
5. A mutant thermostable B-type DNA polymerase according to claim 1 having a Y→N or Y→S mutation.
6. A mutant thermostable B-type DNA polymerase according to claims 1-5 whereas the wild type form is obtainable from Euryarchaea.
7. A mutant thermostable B-type DNA polymerase according to claims 1-6 whereas the wild type form is obtainable from *Thermococcus aggregans*.
8. A mutant of a thermostable B-type DNA polymerase according to claims 1-6 whereas the amino acid sequence of the wild type form is $\geq 80\%$ homologue to the amino acid sequence of wild type *Tag* DNA polymerase.
9. A DNA encoding a thermostable mutant DNA polymerase according to claims 1-8.
10. A vector containing a DNA according to claim 9.

11. A transformed host cell comprising a vector according to claim 10.
12. A process for obtaining a polymerase according to claim 1-8 comprising the steps of cloning and mutagenesis of the gene, followed by the expression and purification of the protein.
13. Use of a polymerase according to claim 1-8 for synthesizing nucleic acids.
14. Use of a polymerase according to claims 1-8 for PCR reactions.

20

EPO - Munich

5

11. März 2000

Abstract

Claimed are thermostable mutants of B-type DNA polymerases having a Y-GG/A amino acid motif between the N-terminal 3'-5'-exonuclease domain and the C-terminal polymerase domain whereas the tyrosine of the Y-GG/A amino acid motif is mutated and whereas these mutant DNA polymerases are suitable for PCR.

THIS PAGE BLANK (USPTO)

EPO - Munich
5
11. März 2000


Figure 1.

Pol activity and Exo activity in %

	WT	Y387F	Y387W	Y387H	Y387N	Y387S	G389A
Pol	100	160	92	93,6	6,4	17,8	10,7
Exo	100	90	71	98	205	187	236
Pol/Exo	1	1,77	1,29	0,96	0,03	0,09	0,04

EPO - Munich
5
11. März 2000

Figure 2






Figure 3




Figure 4





Figure 6

	MW	WT	YF	YW	GA	YS	YN	YH
114	-	-	-	-	-	-	-	-
97	-	-	-	-	-	-	-	-
66	-	-	-	-	-	-	-	-
45	-	-	-	-	-	-	-	-
21	-	-	-	-	-	-	-	-
14	-	-	-	-	-	-	-	-



A

B

Figure 7

	E	R	A	R	G(Y)	K	E	E	L	W	E	consensus
- aggregans	E	Y	R	A	R	I	R	T	T	L	G	YIVIK
- filalis	E	Y	K	R	A	L	R	T	T	L	G	YIVIK
- tumidans	E	L	E	R	A	I	R	G	G	I	A	G YIVIK
- spec. 9N7	E	L	A	R	A	I	R	G	G	I	A	G YIVIK
- gorgonarius	E	L	A	R	A	I	R	E	S	I	A	G YIVIK
- spec. NCD	E	L	A	R	A	I	R	E	S	I	A	G YIVIK
- abyssii	E	Y	E	R	A	I	R	E	S	I	A	G YIVIK
- furirosus	E	Y	E	R	A	I	R	E	S	I	A	G YIVIK
- horikoshii	E	Y	E	R	A	I	R	E	S	I	A	G YIVIK
- jannaschii	E	Y	R	R	A	I	R	E	S	I	A	G YIVIK
- vallis	S	Y	R	E	P	A	X	E	S	I	A	G YIVIK
- scirraticus	T	S	A	L	I	X	G	K	G	I	K	G A V I F E N I
- acidocalcarius	T	A	A	V	I	X	G	K	K	I	K	G A V I F E N I
- islandicum	T	K	A	I	X	G	K	K	I	K	I	G V Y F E N I
- occultum	S	E	A	L	I	X	G	K	K	I	K	G I V Y F E N I
- carnix	V	G	A	I	I	X	D	K	K	I	K	G I V Y F E N I
- onnukensis	T	A	A	I	S	X	G	K	R	I	K	G I V Y F E N I

Figure 8

Figure 9/1

111, 111
ATG ATA TTT GAC ACT GAC TAC ATA AGA AAG GAC GGT AAA CGG ATA ATT CCA ATT TTC AAG
Met Ile Asp Thr Asp Thr Tyr Ile Thr Lys Asp Glu Ile Lys Pro Ile Arg Ile Phe Lys

111, 111
TCA GAG AAC CGG GAA TTT AAA ATA GAA ATT GAT CCA CTT TTT GAG CGG TAC ATT TAC GCT
Ile Glu Asn Gln Glu Phe Ile Glu Leu Asp Pro His Phe Glu Pro Thr Ile Tyr Ala

111, 111
TTT CTG AAA CAT GAC TCC CCT ATT GAT GAA ATA AAA GCA ATA AAA GGC GAG AGA GAC GCA
Leu Ile Ivs Asp Asp Ser Ala Ile Asp Glu Ile Ivs Ala Ile Lys Glu Arg His Glu

111, 111
AAA ATT CTG AGA GCA CTC CAT GCA CTG AAA CCT AAC AAC AAA TTT TTG CGG AGA GAT CCT
Ile Ile Ile Arg Val Val Asp Ala Val Ile Ivs Ivs Phe Leu Glu Arg Asp Val

111, 111
GAG CCT TCG AAG CTT ATA TTT GAG CAT CGG CAA GAC CCT CGG CCT AGC GGC AAG ATA
Glu Val Asp Lys Leu Ile Phe Glu His Pro Glu Asp Val Pro Ala Leu Arg Glu Lys Ile

111, 111
AGC GAA CPT CGA CCT CTG ATT GAC ATT TAT GAG TAC GAC ATA CGG TTT CGG AAG CGG TAC
Asp Gln His Pro Ala Val Ile Asp Ile Tyr Glu Crt Asp Ile Pro Phe Ala Lys Arg Tyr

111, 111
CTG ATA GAC TAC CGC TTG ATC CCT ATG GAG CGG GAC GAG CCT TTT AAG CTA ATG CGG CCT
Leucine Asp Ile Glu Leu Ile Pro Met Glu Glu Asp Glu Glu Ile Lys Leu Met Ala Phe

111, 111
GAC ATT GAG ACC TTT TAC GAC GAG CGA GAC GAG TTT CGG AAG CGG GAG ATA ATA ATG ATA
Asp Ile Glu Thr Pro Thr His Glu Glu Asp Glu Phe Glu Lys Glu Ile Ile Met Ile

111, 111
GCC TAC CGG CAT GAG GAA GAG GCA AGG CTR ATT AGC TCG AAG ATT GAT CCT CGG TAC
Ser Tyr Ala Asp Glu Glu Glu Ala Arg Val Ile Thr Crt Lys Asp Ile Asp Leu Pro Tyr

111, 111
CTT CAT CCT GCA TCC AAC GAA AGG GAG ATG ATA AAG CGG TTT CGG CAA ATT CCT AGG GAA
Val Asp Val Val Ser Asn Glu Arg Glu Met Ile Lys Arg Phe Val Glu Ile Val Arg Glu

111, 111
AAA GAC CGG CAT CCT CTG ATA ACT TAC ATT GCA GAC AAC TTT GAT CCT CGG TAC CCT ATA
Lys Asp Pro Asp Val Leu Ile Thr Tyr Asn Glu Asp Asn Phe Asp Tyr Leu Ile

111, 111
AAA AGC CGA GAG AAC TTA CGA CCT ATT CCT CCT CGG AGG GAC AAA GAA CGC CGG CCT GAG
Ile Arg Ala Glu Ivs Leu Glu Val Thr Leu Leu Glu Arg Asp Lys Glu His Pro Glu

111, 111
CGG AAG ATT GAC AGA ATG CGC CAT AGC TTT CGG CCT GAA ATT AAA GGC AGA ATT GAC TTT
Pro Lys Ile His Arg Met Glu Asp Ser Phe Ala Val Glu Ile Lys Glu Arg Ile His Phe

111, 111
CAT CCT TTG CGG CCT CGG AGA ACC ATA AAC CCT GCA AGC TAC AGC CCT CCT GAG GCA CCT
Asp Leu Phe Pro Val Val Arg Arg Thr Ile Asn Leu Pro Thr Tyr Thr Leu Glu Ala Val

111, 111
TAC GAA CGG CCT TTG CGA AAA ACC AAA AGC AAG CCT CCT CGG CGA GAA ATT CGG CCT CCT
Tyr Glu Ala Val Leu Glu Lys Thr Lys Ser Lys Leu Glu Ala Glu Ile Ala Ala Ile

111, 111
TCC GAA ATA GAG CGG AGC ATG AAG CCT CGG CCT GAC TAC CCT GAA GAT CCT AGG CCT
Tyr Glu Thr Glu Glu Ser Met Lys Leu Ala Glu Ile Lys Ser Met Glu Asp Ala Arg Ala

111, 111
TCT TAT GAA CCT CGA AAA GAG TTT TTG CGG ATG GAG CCT GAG CCT GCA AGG CCT ATA CGG
Tyr Tyr Glu Ile Glu Lys Glu Phe Pro Met Glu Ala Glu Leu Asn Lys Leu Ile Glu

111, 111
CGA AGC CCT TGG GAC CCT TCA AGA TCA AGC ACT CGC AAC CCT CCT GCA GAG CCT CCT CCT
Tyr Ser Val Asp Val Asp Ser Ser Thr Glu Asn Leu Val Glu Crt Tyr Leu Leu

Figure 9/2

1381/35.
ACG CTG CCA TAT GAG ACG AAT GAG CTC CCT CCC AAC AAG CGG GAT GAA GAA GAG TAC AGA
arg val ala tyr glu arg asn glu leu ala pro asn lys pro asp glu gln gln tyr asp

1141/36.
ACG CCT TTA AGC ACT ACT TAC CTC CGA CGA TAC CTC AAA GAG CCC GAA AGA CGG TTA TAC
arg arg leu arg thr thr tyr leu gln gln tyr val lys glu pro glu arg gln leu asp

1001/40.
CAC AAC ATC ACC TAC TTA GAC TTT AGG TCC CTA TAC CCC TCA ATT ATA CCT ACC CAC AAC
gln asn ile thr tyr leu asp phe arg cys leu thr pro ser ile ile val thr his asn

1261/42.
CTG CCT CCT AAC ACT TTA GAA AGA GAA CGC TAC AAC TAC CTC CCT CCC CGG ATA CTC
val ser thr asp thr leu gln arg gln gln cys lys asn thr asp val ala pro ile val

1021/44.
CTT TAT AAC TTC TCC AAC GAT TTT CCT CCT TAC CCT ATA CTC CGG CGA TTA ATC
gln cys phe phe lys asp phe pro gln phe phe ser ile leu gln glu leu ile

1381/46.
ACA ATG AGG CAA GAA ATA AAG AAG AAG ATG AAA CCT ACA ATT AAC CCA ATA CGA AAG AAA
thr met arg gln glu ile lys lys met lys ala thr ile asp pro ile gln lys lys

1441/481.
CTG CCT CAT TAT AGG CAA AGA CCT CCT AAA TAC CGA AAC AGC TAC TAC CCT TAT ATG
met leu asp thr arg gln arg ala val lys leu his ala asn ser tyr tyr tyr met

1361/50.
CCC TAT CCT AAC CGG CGG TCC TAC TCC AAC CGA TCT CGG CGA ACC GT⁴ ACC CGG TCC CGA
gln tyr pro lys ala arg thr tyr ser lys glu cys ala glu ser val thr ala thr gln.

1361/501.
ACG CAC TAC ATA GAA ATG ACC ATA AAA GAG ATA CGG GAG AAA TTT CGA TTT AAC CGG CTC
arg his tyr ile glu met thr ile lys glu ile glu glu lys phe gly phe lys val leu

1521/541.
TAT CCT GAC ACT GAT CCT TTT TAC CCT ACA ATA CGG CGA GAA AAA CCT GAA ACA ATC AAA
tyr ala asp thr asp gln phe tyr ala thr ile phe gly glu lys pro glu thr ile lys

1551/551.
AAC AAA CCT AAG GAA TTC TCA AAA TAC ATA AAC TCC AAA CCT CGG CCT CCT CGG CCT
lys lys ala lys glu phe leu lys tyr ile asn ser lys leu pro gln leu leu glu leu

1541/561.
GAG TAT CGG CGG TTT TAC TCC AGA CGA TTT CCT CCT CGA AAC CGG TAC CCT CGG CCT ATA
gln tyr gln gln phe tyr leu arg gln phe phe val ala lys lys arg tyr ala val ile

1551/561.
CAC CGA CGA CGT AGG ATA ACG ACA AGG CCT CGA CCT CGA AGG AGG GAC TCC AGG GAA
asp glu gln gln arg ile thr thr arg gln leu glu val val arg arg asp thr ser glu

1361/621.
ATA CGG AAA GAG ACC CGG CCT AAA GTC TTG GAG CGA ATA CCT AAA GAA GAT ACT CCT GAA
ile ala lys glu thr gln ala lys val leu glu ala ile leu lys glu asp ser val glu

1321/641.
AAA CCT CCT CGA ATA AGC CCT TTT AGG GAC CCT CCT CGA CGA AAA TAC CGA CCT CGG CCT
lys ala val glu ile val lys asp val val glu glu ile ala lys tyr gln val pro leu

1331/661.
GAA AAC CCT CCT ATC CAC CGG CGG ATT ACC AAG GAT CGA AGT CGA TAC AAA CGG ATT CGG
glu lys leu val ile his glu gln ile ame lys asp leu ser glu tyr lys ala ile gln

1041/681.
CGT CCT CGA CGA ATA CGA CGG CCT CCT CGA AAC CGA ATA AAA CCT CGG CGG CGC ACG
pro his val ala ile ala lys arg leu ala ala lys gln ile lys val arg pro gln thr

1011/701.
ATA ATA AGC TAT ATA CGC CCT CGG CGA AAC CGA AAC ATA AGT CGC AGG CGA ATT CCT CCT
ile ile ser tyr ile val leu arg gln ser gln lys ile ser asp arg val ile leu leu

Figure 9/3

1161, 721

TCA GAG TAT GAT CCC AAA AAA CAC AAC TAC GAC CCC GAC TAC TAC ATA GAA AAC CAA GTT
Ser Glu Tyr Asp Pro Lys Lys His Lys Tyr Asp Pro Asp Tyr Tyr Leu Glu Asn Glu Val

1161, 741

CTG CCC CCC CGG CTT AGG ATC CTT GAA CCC TTC CGG TAC AGA AAA GAG GAC TTG AAA TAC
Leu Pro Ala Val Leu Arg Ile Leu Glu Ala Pro Glu Tyr Arg Lys Glu Asp Leu Lys Tyr

1161, 751

CAA AGG TCA AAA CAG CTT CGA CTG GAC CCC CGG CTT AAC AAC TAC
Gln Ser Ser Lys Glu Val Glu Leu Asp Ala Tyr Leu Lys Arg Amn

THIS PAGE BLANK (USPTO)